The CHECKMATE 040 trial (PD-L1/PD-1) was aimed at assessing nivolumab's safety and efficacy in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis [38]. This evidence concerns the gene CD274 and animal viral hepatitis.